Objective: To assess the safety and feasibility of percutaneous cryoablation on pancreatic cancer via ultrasonography (US) and computed tomography (CT) guidance.Materials and methods: This retrospective review was approved by the institutional review board and of informed consent.Thirty-two patients (18 men and 14 women; median age 62; age range, 30-77 years) with pancreatic cancer (stage Ⅱ/Ⅲ/Ⅳ, 3/11/18) treated with percutaneous US and CT guided cryoablations between February 2009 and February 2010 were eligible for this review.Thirteen tumors in pancreatic head and 19 in pancreatic body and/or tail measuring 2-11 cm (mean, 5.2 cm ± 8 [standard deviation]) were ablated with 49 [standard deviation]) were ablated with 49 procedures in total.Feasibility was analyzed by enhanced CT 1-3 months post procedure and safety was assessed by clinical signs, symptoms and laboratory results.Results: Neither procedural death nor serious complications occurred.Fifteen tumors (46.9%) smaller than 5 cm were successfully ablated by one session of cryoablation.Twenty-seven patients experienced a P50% reduction in pain score, 22 experienced a 50% decrease in analgesic consumption and 16 experienced aP20 increase in Karnofsky Performance Status (KPS) Score.Partial response (PR) and stable disease (SD) turned up in 9 and 21 patients, respectively, lesions in whom were identified controlled by none enhancement on enhanced CT.Mean and median survival was 15.9 and 12.6 months, respectively.The 6-, 12-and 24-month survival rates were 82.8%, 54.7% and 27.3%, respectively.Conclusion: US and CT guided percutaneous cryoablation is a safe and promising local treatment for pancreatic cancer.